The chemical structure submitted to the WHO for the INN vimseltinib is identical to that of the investigational, oral CSF1R inhibitor DCC-3014, via
a PubChem structure match. The compound is claimed as example 10 in Deciphera Pharmaceuticals' patent WO2014145025A2, in which KIT proto-oncogene inhibitory activity is also noted [1
]. Name to structure was formally disclosed in Caldwell et al
. (2022) [2
]. Vimseltinib's selectivity is determined by its interactions within the switch control region of the CSF1R that regulates kinase conformational activation.